KRAS mutations were detected in 52 out of 140 (37.1%) rectal cancer samples (Table 2, Figure 2B), of which 43 (30.7%) samples had mutations in codon 12 and 9 (6.4%) samples had mutations in codon 13 (Table 3). This evidence concerns the gene KRAS and rectal cancer.